vimarsana.com
Home
Live Updates
Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T : vimarsana.com
Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T
'In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy].'
Related Keywords
San Diego ,
California ,
United States ,
New York ,
University Of Rochester ,
American ,
Morphosys Incyte ,
Mazyar Shadman ,
Jonathanw Friedberg ,
Bristol Myers Squibb ,
American Society Of Hematology ,
International Blood Marrow Transplant Research ,
Division Of Medical Oncology ,
Wilmot Cancer Institute ,
University Of Washington ,
Astrazeneca ,
Genentech ,
Medical Oncology ,
American Society ,
International Blood ,
Marrow Transplant Research ,
Samuel Durand Professor ,
Fate Therapeutics ,
Mustang Bio ,
Non Hodgkin Amp 039s Lymphoma ,
Non Hodgkin Lymphoma ,
Hl ,
Biologic Therapy ,
Iologics ,
Chimeric Antigen Receptort Cell Therapy ,
Chimeric Antigen Receptors ,
Himeric Immunoreceptors ,
Himerict Cell Receptors ,
Rtificialt Cell Receptors ,
Art Chimaeric Antigen Receptort Cell Therapy Receptors Immunoreceptors Chimaerict ,
Remission ,
vimarsana.com © 2020. All Rights Reserved.